Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences

Leuk Res. 2011 Nov;35(11):e215-6. doi: 10.1016/j.leukres.2011.07.026. Epub 2011 Aug 15.

Authors

Massimo Breccia, Giuseppina Loglisci, Laura Cannella, Alessandra Serrao, Gioia Colafigli, Adriano Salaroli, Giuliana Alimena

PMID: 21840598
DOI: 10.1016/j.leukres.2011.07.026

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Cholesterol / metabolism*
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Comorbidity
Female
Humans
Hypertension / chemically induced
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Middle Aged
Protein-Tyrosine Kinases / antagonists & inhibitors*
Pyrimidines / therapeutic use*
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Pyrimidines
Cholesterol
Protein-Tyrosine Kinases
nilotinib